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Abstract
Background. Recessive mutations in the NPHS1 gene
encoding nephrin account for ∼40% of infants with con-
genital nephrotic syndrome (CNS). CNS is defined as ste-
roid-resistant nephrotic syndrome (SRNS) within the first
90days of life. Currently, more than 119 different mutations
of NPHS1 have been published affecting most exons.
Methods. We here performed mutational analysis of
NPHS1 in a worldwide cohort of 67 children from 62 dif-
ferent families with CNS.
Results.We found bi-allelic mutations in 36 of the 62 fam-
ilies (58%) confirming in a worldwide cohort that about
one-half of CNS is caused by NPHS1 mutations. In 26
families, mutations were homozygous, and in 10, they
were compound heterozygous. In an additional nine pa-
tients from eight families, only one heterozygous mutation
was detected. We detected 37 different mutations. Nine-
teen of the 37 were novel mutations (∼51.4%), including
11 missense mutations, 4 splice-site mutations, 3 nonsense
mutations and 1 small deletion. In an additional patient
with later manifestation, we discovered two further novel
mutations, including the first one affecting a glycosylation
site of nephrin.
Conclusions. Our data hereby expand the spectrum of
known mutations by 17.6%. Surprisingly, out of the two
siblings with the homozygous novel mutation L587R in
NPHS1, only one developed nephrotic syndrome before
the age of 90days, while the other one did not manifest
until the age of 2years. Both siblings also unexpectedly
experienced an episode of partial remission upon steroid
treatment.
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Introduction
The protein nephrin [1] is an essential component of the
renal glomerular slit diaphragm [2], which is formed by
adjacent glomerular epithelial cells (podocytes). The zip-
per-like structure of the glomerular slit membrane consists
of complexes that contain the molecules neph1 and ne-
phrin, which interact between neighbouring podocyte foot
processes [3]. Nephrin contains eight immunoglobulin-
like domains, a fibronectin type III-like domain, a trans-
membranous domain and a short intracellular domain [1]
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(Figure 1). It plays a significant role in signalling between
podocytes by interacting with molecules like CD2AP and
podocin [3]. Phosphorylated nephrin binds to Nck, an
adapter protein, hereby reorganizing the cell's actin fila-
ment network [4]. Recently, an interaction of the intracel-
lular domain of nephrin with β-arrestin was shown to
attenuate nephrin signalling [5].
Congenital nephrotic syndrome (CNS) is defined as ne-
phrotic syndrome with onset before the 90thday of postna-
tal life [6]. Recessive mutations of the nephrin encoding
gene NPHS1 were initially described in the renal histopath-
ological entity of nephrotic syndrome of the ‘Finnish type’
(CNF) [1]. However, they have more recently also been
found outside Finland [7]. Recently, mutations in nephrin
were shown to cause ∼40% of all cases of CNS [6].
Thedisease is characterizedbymassiveproteinuria caused
by a disruption of the filtration barrier [8]. Due to the mas-
sive protein loss, patients often require central venous albu-
min replacement as well as parental nutrition, leading to a
high mortality from septicaemia. End-stage kidney disease
(ESKD) before the age of 2–3years and resistance to stan-
dard steroid treatment are the rules. To avoid infectious,
thromboembolic and other complications frommassive loss
of protein, including immunoglobulins and coagulation fac-
tors, bilateral nephrectomy, dialysis and renal transplanta-
tion at a body weight of 10kg are recommended [9].
‘Congenital nephrotic syndrome of the Finnish type’
(CNF) [10,11] is exclusively caused bymutations inNPHS1
[1]. Renal histology shows microcystic dilatation of the
proximal tubules and a progressive mesangial sclerosis
[12]. Very recently, rare cases with a manifestation beyond
the age of 90days have also been published, indicating that
different mutations in NPHS1 might cause a spectrum of
clinical severity [13].
To date, 119 different mutations in NPHS1 are known.
To expand the spectrum of known mutations, we per-
formed mutational analysis of NPHS1 by direct sequenc-
ing of all exons in 67 patients from 62 different families
with CNS.
Materials and methods
Patients and data recruitment
DNA samples and clinical data of a worldwide cohort of 2 056 children
with nephrotic syndrome (NS) were ascertained between 1996 and 2008.
The diagnosis was made by paediatric nephrologists on the basis of pub-
lished criteria [14]. Nephrotic-range proteinuria was defined as protein-
uria >40mg/m2/h. After informed consent was obtained, detailed
clinical data and pedigree information were referred to us by the specia-
lists through a standardized clinical questionnaire (www.renalgenes.org)
[15]. For all the patients, we performed mutational analysis of NPHS2
encoding podocin andWT1, the most frequent monogenic causes of child-
hood NS. Human subject research was approved by the University of Mi-
chigan Institutional Review Board and the Ethics Commission of the
University of Freiburg, Germany. Out of this worldwide cohort, we selected
65 children from 62 different families who had CNS and in whom NPHS2
(podocin) andWT1 were excluded. Two patients manifested later, but their
siblings had CNS. Also, mutation analysis in phospholipase C epsilon 1
(PLCE1) was negative for the six patients with CNS who had a renal his-
tology of diffuse mesangial sclerosis (DMS) [16]. In all 67 patients, muta-
tion analysis for NPHS1 was performed by PCR with exon-flanking
primers followed by direct sequencing. When evaluating frequency of mu-
tations, we relate them to families rather than patients because siblings have
identical mutations. When evaluating clinical data, we relate them to pa-
tients because siblings might differ in clinical phenotype.
Mutation analysis
Genomic DNAwas isolated from blood samples using the Puregene® DNA
purification kit (Gentra, Minneapolis, MN) following the manufacturer's
guidelines. Mutation analysis was performed by direct sequencing of all
29 exons of NPHS1, all eight exons of NPHS2 and exons 8 and 9 of
WT1.WT1 analysis was limited to exons 8 and 9 because mutations of this
gene accounting for isolated NS have only been reported in these two exons
[17,18]. Additionally, for seven patients with a renal histology of DMS, all
exons of PLCE1 were examined by direct sequencing. Exon-flanking pri-
mers forNPHS1, PLCE1,NPHS2 andWT1 have been published previously
[15,16,18,19]. For sequence analysis, the software Sequencher 3.8 (Gene
Codes, Ann Arbor, MI) was used. As reference for NPHS1, the published
wild-type sequence (NM_004646) was used for nucleotide and amino acid
Fig. 1. Localization of mutations in nephrin. The nephrin protein consists of eight extracellular Ig-like domains (Ig 1–8), a fibronectin type III-like
module (Ig, FN3), a transmembrane domain (Ig) and a C-terminal (C) cytoplasmic domain (curled line). The grey/white background delimits the exons
coding for the corresponding protein domains. All mutations found in this study are listed (novel mutations—white on black; known mutations—black
on white). Note that mutations were spread throughout the protein with predominance of Ig-like domain 5. The patient harbouring these mutations was
not included in the study cohort (asterisk).
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Table 1. All NPHS1 mutations detected
Patient number Exon Nucleotide exchangea Effect on coding sequence Mutation statusb Segregation Reference
Homozygous mutations
A2471 4 c.C500T p.P167L Hom p,m ps
A2201 4 c.514_516delACC p.T172del Hom nd Lenkkeri et al. 1999
A3023 8 c.C896T p.R299C Hom nd ps
A2911 9 c.C1019A p.P340H Hom nd ps
A1176 9 c.G1040A p.G347E Hom nd ps
A2031 9 c.A1096C p.S366R Hom nd Lenkkeri et al. 1999
A2617 9 c.C1099T p.R367C Hom nd Lenkkeri et al. 1999
CNS11 II-1 9 c.G1134A p.W378X Hom ? ps
CNS11 II-2 9 c.G1134A p.W378X Hom ? ps
A2300 10 c.C1219T p.R407W Hom p,m ps
A1804 11 c.G1379A p.R460Q Hom nd Beltcheva et al. 2001
CNS09 II-1 13 c.C1672T p.R558C Hom ? Beltcheva et al. 2001
CNS09 II-2 13 c.C1672T p.R558C Hom ? Beltcheva et al. 2001
A2417 13 c.A1757G p.R586G Hom p,m ps
A945 14 c.1759-15_1778del Splice error Hom p,m ps
A2236 II-1 14 c.T1760G p.L587R Hom p,m ps
A2236 II-2 14 c.T1760G p.L587R Hom p,m ps
A2355 14 c.T1760G p.L587R Hom p,m ps
CNS05 14 c.G1868T p.C623F Hom ? Lenkkeri et al. 1999
A2330 20 c.2815+5G>A Splice error Hom p,m ps
F1273 20 c.2664-4_2670del Splice error Hom nd Heeringa et al. 2008
CNS03 21 c.2927+1G>A Splice error Hom ? ps
A2088 24 c.3243_3250insG p.1084fsX12 Hom nd Kestila et al. 1998
A2538 24 c.3243_3250insG p.1084fsX12 Hom nd Kestila et al. 1998
A3075 24 c.3243_3250insG p.1084fsX12 Hom nd Kestila et al. 1998
A2553 26 c.C3325T p.R1109X Hom nd Kestila et al. 1998
CNS12 27 c.3481+1G>T Splice error Hom ? Beltcheva et al. 2001
A2210 II-1 28 c.C3478T p.R1160X Hom nd Lenkkeri et al. 1999
A2210 II-3 28 c.C3478T p.R1160X Hom nd Lenkkeri et al. 1999
A2036 28 c.C3478T p.R1160X Hom nd Lenkkeri et al. 1999
Compound heterozygous mutations
A2341 1 c.58+1G>T Splice error Cpd het m ps
3 c.C320T p.A107V p ps
A2535b 5 c.C574T p.Q193X Cpd het nd ps
20 c.T2728C p.S910P nd ps
A1943 6 c.613_620delinsTT p.T205,P206,R207>I205 Cpd het nd Lenkkeri et al. 1999
13 c.G1715A p.S572N nd Gigante et al. 2005
A2616 6 c.613_620delinsTT p.T205,P206,R207>I205 Cpd het m Lenkkeri et al. 1999
22 c.G2928T p.R976S p ps
CNS01 8 c.G886A p.W289X Cpd het ? ps
14 c.T1760G p.L587R ? ps
CNS08 9 c.T1048C p.S350P Cpd het ? Lenkkeri et al. 1999
19 c.G2625A p.W875X ? ps
A2030 9 c.A1096C p.S366R Cpd het nd Lenkkeri et al. 1999
24 c.C3478T p.R1160X nd Lenkkeri et al. 1999
A3083 9 c.C1019A p.P340H Cpd het nd ps
24 c.C3478T p.R1160X nd Lenkkeri et al. 1999
A2475A1981 15 c.G2043T c.W681C Cpd het p ps
17 c.2227delC p.R743fsX10 m ps
15 c.C2019A p.N673K Cpd het p ps
24 c.C3478T p.R1160X m Lenkkeri et al. 1999
A2249 17 c.C2227T p.R743C Cpd het nd Lenkkeri et al. 1999
27 c.C3442T p.Q1148X nd Beltcheva et al. 2001
Single mutations only
A2618 3 c.C320T c.A107V het sm m ps
A2380 10 c.G1223A c.R408Q het sm nd Lenkkeri et al. 1999
A1869 11 c.G1379A c.R460Q het sm nd Beltcheva et al. 2001
A1517 14 c.G1868T c.C623F het sm nd Lenkkeri et al. 1999
A2250 17 c.C2227T c.R743C het sm nd Lenkkeri et al. 1999
A2062 19 c.G2625A c.W875X het sm p ps
A2320 II-1 23 c.C3418T c.R1140C het sm nd Lenkkeri et al. 1999
A2320 II-2 23 c.C3418T c.R1140C het sm nd Lenkkeri et al. 1999
As relevant wild-type gene sequence, the published reference sequence of NPHS1 was used (NM_004646). het, heterozygous; Hom, homozygous
mutation; cpd het, compound heterozygous mutation; sm, single mutation only detected; p, paternal; m, maternal; nd, not done; ?, information not
available for this patient; ps, novel mutation detected in the present study.
aAll mutations were absent from 93 healthy controls.
bPatient was not included in the study.
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numbering. For all detected mutations and variants, both strands were se-
quenced. Whenever possible, segregation was confirmed by direct se-
quencing of the parental samples. For novel mutations, their absence
from 93 healthy control individuals was confirmed by direct sequencing.
Homozygosity mapping
Genome-wide homozygosity mapping for 12 families with CNS was per-
formed and evaluated as described previously [20]. Single-nucleotide
polymorphism (SNP) arrays (GeneChip®) from Affymetrix, Inc. with a
resolution of 250K (Human Mapping 250K Styl Array) were used.
Samples were processed, hybridized and scanned using the manufac-
turer's standard methods at the University of Michigan Core Facility
(www.michiganmicroarray.com). Using the software Allegro [21] and
ALOHOMORA [22], non-parametric likelihood ratio Z-scores (ZLRs)
were calculated using one marker every 100 000 markers. Allele frequen-
cies for Caucasians as specified by Affymetrix®, a disease allele frequency
of 0.001, and a standard pedigree structure assuming first-cousin marriage
for parents of affected individuals were used. ZLRs were calculated under
three different conditions, i.e. for minor allele frequencies of >0.2, >0.3 and
>0.4, and a non-existent sibling was included to enable non-parametric Al-
legro runs. If a peak was constantly exceeding the value of 2.0 in two out of
the three conditions, we referred to it as a ‘consistent ZLR peak’ (cZLR)
and expected it to harbour the homozygous mutation of the recessive
disease gene [20]. The ZLRs were plotted against genetic distance
across the entire human genome using the Gnuplot software (http://
www.gnuplot.info) (Supplementary Figure 1; see online supplementary
material for a colour version of this figure). In this way, the maxima of
ZLR scores represent segments of homozygosity by descent.
Results and discussion
Clinical characteristics and ethnicity of patients
In this study, 67 patients (32 females, 34 males and 1 with
unknown gender) from 62 different families with CNS were
included. All patients were examined forNPHS1mutations.
Renal biopsy was performed in 24 patients, showing 10
with a pattern congruent to NS ‘Finnish type’, 8 patients
with DMS, 3 with minimal change nephrotic syndrome
(MCNS), 2 with focal segmental glomerulosclerosis
(FSGS), 1 with membranoproliferative glomerulonephritis
(MPGN) and 1 with end-stage nephrosclerosis (Supplemen-
tary Table 2). Altogether, 21 different ethnicities were repre-
sented within the cohort; among these, the largest groups
were of Turkish (15%), Arabic (15%), European (13%)
and Caucasian (9%) descent (Supplementary Table 2).
Consanguinity was reported in 20 families (Supplementary
Table 1). In three cases, a nephrectomy had been per-
formed, and 10 patients had received a renal transplant
(Supplementary Table 2).
Modality of treatment and response
Because traditionally CNS is considered treatment refrac-
tory, steroid treatment was only reported as attempted in 14
(20.8%) cases. Eleven of these patients showed no re-
sponse (steroid-resistant nephrotic syndrome, SRNS), as
expected for CNS, while three (A2236 II-1/II-2, A2380)
did partially respond. In four cases, cyclosporin A was ap-
plied in addition to steroids, while one patient was treated
with cyclosporin A only (Supplementary Table 2). In none
of these subjects was any response recorded (Supplemen-
tary Table 2, Supplementary Table 4).
‘Antiproteinuric therapy’ with angiotensin-converting
enzyme (ACE) inhibitors or indomethacin was attempted
in 34 patients. In nine patients, exclusively ACE inhibitors
were applied, of which two (22.2%) showed a partial remis-
sion (A1804, A2475). Partial remission is hereby under-
stood as the permanent disappearance of oedema, an
increase in the serum albumin concentration to >35g/L
and the persistence of proteinuria of >4mg/m2/h [23]. In
both patients, mutation analysis had revealed disease-caus-
ing mutation in NPHS1. Surprisingly, A2475 showed com-
pound heterozygosity for a missense mutation and a
deletion. A combined therapy with indomethacin and
ACE inhibitors was administered to 26 patients of which
eight (30%) showed partial remission, while in 17 cases,
no effect was observed. Of the eight patients showing a par-
tial remission, a disease-causing mutation in NPHS1 was
found in six patients. Of these six patients, missense muta-
tions were disease causing in five cases. Unexpectedly,
however, patient A2201 also showed partial remission, al-
though a homozygous deletion was detected in this patient.
He was treated with captopril for 40months followed by
10months of treatment with losartan. Indomethacin was
applied for 3months but did not show any benefit. These
data show that ‘antiproteinuric’ therapy has a beneficial
effect on 20–30% of patients with CNS and should not
only be considered for patients with missense mutations
but might also be positive for patients with a more severe
type of mutation (Supplementary Table 2, Supplementary
Table 4).
For 19 out of the 67 patients, no pharmacological treat-
ment was reported.
NPHS1 mutations
In 67 children from 62 different families, mutation analysis
by direct sequencing of all NPHS1 exons was performed.
In 36 families, causative mutations in NPHS1 were de-
tected on both alleles. We hereby confirm the results of
former studies [6,19] showing that approximately one-half
of CNS cases are caused by recessive mutations in NPHS1
(Table 1). In CNS, it has been shown that ∼85% of the
cases are explained by mutations in four genes. The distri-
bution among these four genes is: NPHS1 39.8%, NPHS2
39.8%, WT1 2.2% and LAMB2 4.4% [6]. Twenty-six of the
36 families showed homozygous mutations, and another
10 families had compound heterozygous mutations. In
seven families, only one heterozygous NPHS1 mutation
was detected (Table 1). As a reason for this relatively high
number of patients with disease-causing mutations, only on
one allele, one might speculate that deletions/duplications
of whole exons as well as intronic mutations and mutations
in the promoter region can explain these cases. A direct
sequencing approach might not have been able to detect
these mutations.
Out of the 37 different disease-causing NPHS1mutations
detected, 19 mutations were novel, consisting of 11 mis-
sense mutations, 4 splice-site mutations, 3 nonsense muta-
tions and 1 deletion. They were found in exons 1, 3, 4, 8, 9,
10, 13, 14, 15, 17, 19 and 21 (Table 1 and Figure 1, Supple-
mentary Figure 1; see online supplementary material for a
colour version of this figure). The 18 previously published
mutations consisted of 10 missense mutations, 3 nonsense
mutations, 1 insertion, 1 deletion, 2 splice-site mutations
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and 1 insertion/deletion. They were found in exons 4, 6,
9, 10, 11, 13, 14, 17, 20, 22, 24, 26 and 27 (Table 1,
Figure 1). None of the patients had the Finmajor or the
Finminor mutation. The mutations were broadly distributed
over the nephrin protein, affecting all domains. The most
frequently affected domains were immunoglobulin (Ig)-like
domain 5 and Ig-like domain 3 (Figure 1).
Genotype/phenotype correlations
While the CNS classical histology of ‘Finnish type’ rapidly
progresses into ESKD and shows no response to treatment,
several cases of patients with NPHS1 mutations have been
reported, whose histological phenotype was not as severe
and who sometimes even showed a response to treatment
[19,24].
From the 12 patients in our study, in whom renal biopsy
was performed and whose disease was explained by two
recessive mutations in NPHS1, eight patients showed NS
‘Finnish type’, three showed MCNS, one showed DMS
and one showed FSGS (Supplementary Table 3). These da-
ta confirm the previous finding that renal pathology does
not exclusively appear as NS ‘Finnish type’ in CNS caused
by recessive NPHS1 mutations. A higher frequency of mu-
tations in a certain ethnicity was not observed.
Out of the seven patients in our cohort with a biopsy of
DMS, only one had disease-causing NPHS1 mutations
(A2911 II-1). This patient showed a novel homozygousmis-
sense mutation (c.1019C>A, p.P340H) (Table 1). The pa-
tient was steroid resistant. Manifestation was at birth, and
ESKD developed at the age of 4months (Supplementary
Table 1). Another patient (A3083 II-1) showed the same
mutation heterozygously together with a heterozygous
known nonsense mutation [c.3478 C>T (h), p.R1160X]
(Table 1). He manifested at the age of 2months and also
showed steroid resistance. Biopsy was not performed, and
ESKD was not reported by the age of 6months (Supple-
mentary Table 1). DMS is seen in patients with mutations
in PLCE1, WT1 and LAMB2. As WT1 and PLCE1 yielded
no mutations in the remaining DMS patients, we speculate
that they may have mutations in LAMB2 or PLCE1.
One patient (A2616 II-1) with a biopsy of FSGS
showed compound heterozygosity for a known deletion
(c.613_620delinsTT; p.T205, P206, R207>I205) and a
novel missense mutation [c.2928G>T (h), p.R977S]
(Table 1). The age of disease onset was 2months, and
steroid treatment was not attempted. The patient devel-
oped ESKD by the age of 10years and was transplanted
(Supplementary Table 1).
In two patients with a homozygous NPHS1 mutation
(CNS03, CNS11 II-1), a renal biopsy of MCNS was re-
ported. Patient CNS03 II-1 had a truncating mutation
[c.1134G>A (H), p.W378X], while patient CNS11 II-1 had
a splice-site error (c.2927 +1G>A, splice error) (Table 1). In
both cases, no treatment was attempted. The age of onset for
patient CNS03 was shortly after birth, and patient CNS11
II-1 manifested later at the age of 4months. For patient
CNS11 II-2, no biopsy was performed; both siblings were
treated with steroids for 2months but did not respond (Sup-
plementary Table 1). Patient CNS03 showed severe progres-
sion with nephrectomy at the age of 6months and histology
of glomerulosclerosis as well as tubular atrophy, microcysts
and interstitial fibrosis. As patients with an early biopsy of-
ten show MCNS but progress rapidly, the aetiopathology of
this patient is not surprising. However, patient CNS11 II-1 is
reported to be stabile at the age of 2.5years now and, togeth-
er with the late onset, is showing a rather unusual course of
disease. Both siblings also showed partial remission to treat-
ment with ACE inhibitors and indomethacin.
Althoughmutations inNPHS1were thought to exclusive-
ly cause CNF, these results confirm former findings indicat-
ing that NPHS1 mutations can cause a somewhat broader
variety of histological phenotypes in nephrotic syndrome.
In a recent genetic study of patients with CNS [6], in a total
of 21 patients with two NPHS1 mutations, the histological
phenotypes were distributed as follows: ‘Finnish type’
(14%), MCNS (14%), FSGS (4.6%), DMS (3.6%), mesan-
gial proliferation (9.2%), mesangial sclerosis (3.6%) and no
finding (3.6%) [6] (Supplementary Table 3). In 10 patients,
no biopsywas performed. These resultswere also confirmed
by another study of children with CNS, showing again ‘non-
Finnish type’ manifestations [19] (Supplementary Table 3).
While the CNS classical histology of ‘Finnish type’ rap-
idly progresses into ESKD and shows no response to treat-
ment, several cases of patients with NPHS1 mutations have
been reported, whose histological phenotype was not as
severe and who sometimes even showed a response to treat-
ment [19,24]. Recently, Phillipe et al. even reported several
cases with childhood rather than congenital onset of ne-
phrotic syndrome and confirmed mutations in NPHS1
[13]. In this study, two siblings were included who had dif-
ferent age of onset. While the male sibling (A2236 II-2)
manifested as CNS by the age of 2.5months, his elder sister
(A2236 II-1) stayed healthy until the age of 24months. Both
showed partial remission due to steroid treatment, and in
both sibs, a novel homozygous missense mutation
(c.1760T>G, p. L587R) was detected. Partial remission is
hereby understood as the permanent disappearance of oe-
dema, an increase in the serum albumin concentration to
>35g/L and the persistence of proteinuria of >4mg/m2/h
[23]. A third patient (A2355 II-1), who was classified as
CNS and of the same ethnicity, showed the same mutation.
Interestingly, he also was not diagnosed before the age of 5
months. Steroid treatment for this patient was not attempted.
Additionally, one patient (CNS01) showed L587R hetero-
zygously in combination with a heterozygous nonsense mu-
tation [c.886G>A (h),W289X]. This patient showed the age
of onset of 2months, and no form of steroid treatment was
reported. We therefore conclude that homozygous L587R
may be a milder mutation, causing a less severe form of ne-
phrotic syndrome than other NPHS1 mutations with possi-
ble childhood onset later than 90days of life. It is, to our
knowledge, the first homozygous mutation in NPHS1 to
cause childhood onset (in A2236 II-1 and A2355 II-1),
and the findings suggest that mutation analysis should also
be sought in children who manifest after 90days of life.
Detection of NPHS1 mutations by total genome
homozygosity mapping
Mutations that are homozygous by descent have been
described as being frequent (30–80%) in paediatric dis-
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eases [20]. This can be mapped by homozygosity map-
ping. In order to investigate if homozygosity mapping is
a useful tool for screening, we performed homozygosity
mapping in a subset of this cohort of 12 patients from
12 families with different background (Supplementary
Table 1). All of them exhibited homozygous segments
by inspection of their homozygosity plots, while only
five (A2031 II-1, F1273 II-1, A1804 II-1, A2088 II-1,
A2036 II-1) revealed homozygosity at the NPHS1 locus
(Supplementary Figure 2; see online supplementary ma-
terial for a colour version of this figure). We detected
homozygous disease-causing mutations of NPHS1 in
all five patients. Of the remaining seven patients, two
(A1981 II-1, A2062 II-1) showed compound heterozy-
gous disease-causing mutations, two (A1517 II-1, A1869
II-1) showed single heterozygous mutations and three
(A1970 II-1, A1980 II-1, A2112 II-1) showed no mutations
of NPHS1 (Table 1, Supplementary Table 1).
Mutation in N-glycosylation site
In addition to the results of our systematic mutation
screening in a CNS cohort, we report on a single patient
with onset of nephrotic syndrome at the age of 9months
who was also found to be mutated in NPHS1. The patient
was not included in the study, and his clinical data is not
shown here. He was treated with steroids but did not re-
spond (SRNS). His renal biopsy showed the histological
features of IgM nephropathy.
Mutation analysis of NPHS1 in patient A2535 revealed
two novel heterozygous mutations: c.574C>T; p.Q193X
and c.2728T>C; p.S910P (Table 1, Figure 1, not included
in the examined cohort). This finding is of interest as, to
our knowledge, S910P is the first mutation described, which
directly affects one of nephrin's ten known N-glycosylation
sites [25]. Substitution of the serine residue by proline is
predicted to prevent glycosylation at this site. Defects in
post-translational modification may lead to decreased
stability of impaired interaction with other molecules.
Considering the late manifestation of nephrotic syn-
drome in this patient, we speculate that the mutation
S910P has some residual protein function and might
be a ‘mild’ mutation. As it has been described recently,
a ‘mild’ mutation in combination with a ‘severe’ muta-
tion in NPHS1 may cause childhood onset of nephrotic
syndrome [13].
Adding these mutations, we here report 21 novel muta-
tions, expanding the number of published mutations in
NPHS1 by 17.6%.
Supplementary data
Supplementary data is available online at http://ndt.oxford-
journals.org.
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Abstract
Background. Little information is available on a long-
term follow-up in Bartter syndrome type I and II.
Methods. Clinical presentation, treatment and long-term
follow-up (5.0–21, median 11 years) were evaluated in
15 Italian patients with homozygous (n = 7) or compound
heterozygous (n = 8) mutations in the SLC12A1 (n = 10) or
KCNJ1 (n = 5) genes.
Results. Thirteen new mutations were identified. The
15 children were born pre-termwith a normal for gestational
age body weight. Medical treatment at the last follow-up
control included supplementation with potassium in 13,
non-steroidal anti-inflammatory agents in 12 and gastropro-
tective drugs in five patients. At last follow-up, body weight
and height were within normal ranges in the patients. Glo-
merular filtration rate was <90 mL/min/1.73 m2 in four
patients (one of them with a pathologically increased uri-
nary protein excretion). In three patients, abdominal ul-
trasound detected gallstones. The group of patients with
antenatal Bartter syndrome had a lower renin ratio (P <
0.05) and a higher standard deviation score (SDS) for
height (P < 0.05) than a previously studied group of pa-
tients with classical Bartter syndrome.
Conclusions. Patients with Bartter syndrome type I and II
tend to present a satisfactory prognosis after a median fol-
low-up of more than 10 years. Gallstones might represent a
new complication of antenatal Bartter syndrome.
Keywords: Bartter syndrome; cholelithiasis; growth retardation; KCNJ1
gene; SLC12A1 gene
Introduction
Bartter syndrome type I (BS I) and type II (BS II) are salt-
wasting renal tubular disorders that are clinically character-
ized by polyhydramnios leading to premature delivery,
marked polyuria and a tendency towards nephrocalcinosis
[1,2]. Loss-of-function mutations either in the furosemide-
sensitive sodium–potassium–chloride cotransporter gene
(SLC12A1; BS I, OMIM 601678) or in the inwardly rectify-
ing potassium channel ROMK gene (KCNJ1; BS II, OMIM
241200) have been identified in the vast majority of patients
with this autosomal recessive disorder [3,4]. Mutations in
the CLCNKB chloride channel gene (Bartter syndrome type
III also defined as classical Bartter syndrome—OMIM
607364) aswell as in the BSNDgene (Bartter syndrome form
associated with sensorineural deafness—Bartter type IV—
OMIM 602522) are also sometimes responsible for an iden-
tical clinical phenotype but will not be treated in this report.
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